Skip to content

Impact on Quality of Life of Endo-App (ELEA)

Impact on Quality of Life by Additional Use of the Digital Health Application Endo-App to Standard Therapy: Monocentric, Prospective, Randomised Trial (ELEA)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04883073
Acronym
ELEA
Enrollment
300
Registered
2021-05-12
Start date
2023-01-26
Completion date
2023-09-01
Last updated
2024-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis, Endometriosis-related Pain, Quality of Life

Keywords

endometriosis, quality of life, Endo-App, EHP-5, Endometriosis Health Profile, digital therapeutics

Brief summary

monocentric randomized controlled trial enrolment of endometriosis patients from certified endometriosis centers. Randomization to control group (no Endo App use) vs intervention group (Endo App use) 12 weeks use / no use of Endo App. Evaluation of quality of life at onset, at 4, 8 and 12 weeks by using endometriosis health profile (EHP) 5 as a global index. Statistical analysis of global index at the end minus global index at onset between control and intervention group.

Detailed description

randomized controlled trial enrolment of patients with diagnosed endometriosis 300 patients in total, 150 patients per group, randomization to control group (no Endo App use) vs intervention group (12 weeks Endo App use). The Endo App is a german language certified medical device which can be used to monitor the disease and gives support by providing complementary, multimodal interventions to standard therapy and is commercially available. Purpose of this study is the evaluation of quality of life at onset and then at 4, 8 and 12 weeks by using endometriosis health profile (EHP) 5 as a global index. The secondary endpoints of this study to evaluate are Fatigue symptoms (FSSsurvey), pain- specific self-efficacy (FESS), difficulty in everyday life due to pain (PDI) and emotional wellbeing (DASS- 21)

Interventions

DEVICEUse of Endo App

Use of Endo App

Sponsors

Endo Health GmbH
CollaboratorINDUSTRY
University Hospital Muenster
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

monocentric single side blinded randomized controlled trial

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Legal capacity * Living in Germany * Adequate german language skills * Female biological gender * Ages eligible for study ≥ 18 years * Medical Diagnosis of endometriosis Diagnosis verification by following documents: 1. Operation Report 2. Histological finding 3. MRI finding 4. Other medical examination documents with endometriosis diagnosis (for example sonography, colonoscopy, cystoscopy) Owning a smartphone and having an internet access Willingness and capability of using the smartphone device and the Endo App Motivation to regularly fill out the questionnaries Owning an e-mail address for App registration Absence of exlusion criteria

Exclusion criteria

* Absence of inclusion criteria * Pregnancy existing at survey period * Ongoing hormonal fertility treatment or planned treatment within the next 12 weeks (artificial insemination as part of in vitro fertilization, such as IVF or ICSI, hormone injections for fertility treatment) * Ongoing or within the next 12 weeks planned rehabilitation or multimodal pain therapy * Planned change in hormone therapy (change of active substance, new start or discontinuation of therapy) in the next 12 weeks or change in hormone therapy within the last 8 weeks before the start of the study * Endometriosis surgery planned in the next 12 weeks or endometriosis surgery performed within the last 8 weeks prior to study start * Previous or existing access to Endo app or current prescription

Design outcomes

Primary

MeasureTime frameDescription
EHP 512 weeksChange in Endometriosis Health Profile 5 (minimum value: 0 points, maximum value: 100 points, higher scores mean a worse outcome)

Secondary

MeasureTime frameDescription
FSS survey12 weeksChange over course of study
FESS survey12 weeksChange over course of study
PDI survey12 weeksChange over course of study
DASS-21 survey12 weeksChange over course of study
EHP 54 weeksChange between 1st and 2nd survey

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026